September 6th 2024
"The urgency to increase awareness about prostate cancer is underscored by our most recent data and analysis," says William L. Dahut, MD.
Technology doesn’t raise overall PCa therapy rate
July 24th 2013The rate of therapy for localized prostate cancer does not rise in markets with higher penetration of robotic surgical technology and intensity-modulated radiation therapy, according to a study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Semi-annual PSA may be safe for men on surveillance
July 18th 2013Some men with low-risk prostate cancer who are being managed by active surveillance can have their PSA levels measured every 6 months instead of every 3 months, researchers reported at the American Society of Clinical Oncology annual meeting in Chicago.
Diabetes drug lowers prostate cancer-specific, all-cause mortality
July 18th 2013In men with diabetes who are diagnosed with prostate cancer, use of metformin reduces both cancer-specific and all-cause mortality, and the treatment benefits increase with increasing cumulative duration of exposure to the drug, according to the results of a retrospective study presented at the American Society of Clinical Oncology annual meeting in Chicago.
Men still want PSA; shared decision making uncommon
July 15th 2013Men plan to continue getting PSA tests despite the U.S. Preventive Services Task Force’s recommendation against screening, but just over one-third of men report shared decision making for screening with their physician, according to findings from two recently published studies.
Prostate cancer surveillance questioned for African-Americans
July 1st 2013A study of more than 1,800 men ages 52 to 62 years suggests that African-Americans diagnosed with very low-risk prostate cancers are much more likely than Caucasian men to actually have aggressive disease that goes unrecognized with current diagnostic approaches.
Observation safe, cost effective for low-risk prostate cancer
June 24th 2013Observation appears to be safe and more cost effective than immediate treatment for many men with low-risk, localized prostate cancer, according to a recent study from Dana-Farber Cancer Institute and Massachusetts General Hospital, Boston.
PET/MR imaging efficacious for mapping recurrent prostate cancer
June 17th 2013A relatively new imaging system demonstrates a higher capacity for mapping recurrent prostate cancer than integrated positron emission tomography and computed tomography, researchers recently reported at the Society of Nuclear Medicine and Molecular Imaging annual meeting in Vancouver, British Columbia.
Prostate cancer screening guideline: Shared decision making key
June 17th 2013A new AUA guideline on the early detection of prostate cancer is a PSA-focused, evidence-based guideline intended to assist the urologist in advising an average-risk, asymptomatic man about prostate cancer screening in order to reduce prostate cancer mortality, said H. Ballentine Carter, MD, at the AUA annual meeting in San Diego.
Novel advanced prostate cancer treatment significantly improves survival
June 17th 2013Results from the primary endpoint analysis in a phase III randomized, placebo-controlled study showed that intravenous radium Ra 223 dichloride (Xofigo), an alpha-particle-emitting radiotherapeutic agent and calcium mimetic that binds to newly formed bone stroma, significantly improved overall survival in castration-resistant prostate cancer patients with bone metastases.
AUA castration-resistant prostate cancer guideline seeks to clarify decision making
June 12th 2013The AUA has released its first-ever clinical practice guideline for castration-resistant prostate cancer, and all urologists who care for men with advanced prostate cancer should familiarize themselves with its contents, said Michael S. Cookson, MD, who presented the new guideline at the AUA annual meeting in San Diego.
Agent active in PCa patients with BRCA mutations
June 3rd 2013In what is being called the largest clinical trial to examine the efficacy of poly(ADP-ribose) polymerases (PARP) inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced forms of both prostate and pancreatic cancer.
Analysis supports use of prostate cancer agent in chemo-naive men
May 24th 2013Data from a third planned interim analysis of a phase III trial are consistent with earlier results supporting the efficacy and safety of abiraterone acetate (Zytiga) as a treatment for chemotherapy-naïve men with metastatic castration-resistant prostate cancer.